Speaker illustration

Professor Steve Bain

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)

Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme

Event: ESC Congress 2018

Topic: Antidiabetic Pharmacotherapy

Session: Cardiac patients with comorbidities

Thumbnail

Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Event: ESC Congress 2018

Topic: Antidiabetic Pharmacotherapy

Session: Cardiovascular risk and its modification

Thumbnail

Connect with the speakers: questions & answers.

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Joining clinical practices: cardiovascular disease and type 2 diabetes

Thumbnail

Linking the dots: cardiovascular disease, type 2 diabetes and other comorbidities.

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Joining clinical practices: cardiovascular disease and type 2 diabetes

Thumbnail

This platform is supported by

logo Novo Nordisk